Form 4: Akero Therapeutics Senior VP Sells Shares for Tax Obligations

Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, sold 875 shares of common stock for $54.59 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Patrick Lamy, Senior VP, Commercial Strategy at Akero Therapeutics, Inc. (AKRO), reported a sale of common stock.
• The transaction occurred on June 20, 2025.
• A total of 875 shares were disposed of at a price of $54.59 per share.
• Following this transaction, Patrick Lamy beneficially owns 31,698 shares of common stock.
• The sale was a "sell-to-cover" transaction, meaning the shares were sold automatically to satisfy tax withholding obligations associated with the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell-to-cover' for tax purposes related to RSU vesting, which is a neutral event from an investment sentiment perspective. It is not indicative of discretionary selling or a change in management's outlook.

Positives

• The sale indicates the vesting of restricted stock units, which is a positive event for the employee, Patrick Lamy, as it represents compensation earned.
• The "sell-to-cover" policy ensures a structured and non-discretionary method for employees to meet tax liabilities from equity compensation.

Negatives

• The transaction resulted in a reduction of Patrick Lamy's direct beneficial ownership in Akero Therapeutics by 875 shares.

Risks

• No specific risks are detailed in this Form 4 filing beyond the transaction itself.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, particularly in companies that grant equity compensation like restricted stock units. It does not provide specific insights into broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• This document, being a routine insider transaction for tax purposes, does not contain information that allows for a direct comparison to global benchmarks, specific comparable companies, projects, or results. 'Sell-to-cover' transactions are standard practice for equity compensation across various industries.

Stakeholder Impact

• Shareholders: A very minor, non-discretionary reduction in insider ownership. Generally, such small, tax-related sales have negligible impact on shareholder sentiment or share price.
• Employees: The vesting of restricted stock units is positive for the employee (Patrick Lamy) as it represents earned compensation.

Next Steps

• The document does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Keywords

Akero Therapeutics, AKRO, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Patrick Lamy, Biotechnology, Pharmaceuticals